Advent Energy Limited (“Advent”) (BPH 35.8% Direct interest) PEP-11 permit
Advent Energy Limiteds100% Subsidiary Asset Energy PTY LTD (“Asset”) is a participant in the Pep11 -Joint venture with partner Bounty Oil and Gas NL (ASX: Buy). PEP-11 Interests are:
Advent Energy 85 % / Bounty Oil and Gas 15 %
On January 17, 2025, the PEP-11 Joint Venture of Nopta was informed that the Joint Authority refused the Joint Venture applications on January 23, 2020 and 17 March 2021 and that the PEP-11 permit would remain in force for a period of 2 months from January 17, 2025 (the “decision”).
On 12 February 2025, BPH announced that assets had applied for the federal court for an original application (the “application”) for judicial assessment in 5 of the administrative decisions (judicial evaluation) ACT 1977 (CTH) and S 39b of judicial law 1903 (CTH) to revise the decision. The application is looking:
1. An order that destroys or sets the decision aside;
2. A statement that the decision is void and no effect; And
3. An order that contains the first application and the second application for the joint authority for reconsideration according to the law.
On March 17, 2025, the Federal Court delivered orders with permission that was further explained in the company 2025 report of the company.
The parties have met all programming assignments and the case is now mentioned for hearing on 16 and 17 September 2025.
There were no further developments during the quarter of June 2025.
PEP-11 remains in force and the joint venture is in accordance with the contractual conditions of PEP11 with regard to matters such as reporting, payment of rental prices and the various provisions of the offshore Petroleum and greenhouse gas storage Act 2006 (CTH).
Cortical Dynamics Limited (Cortical) (BPH 16.4% Direct interest)
Technical completion of the next generation AI from Cortical AI improved brain and pain monitoring bar 2.0 will be expected in the coming months.
BARM 2.0 is the only solution that unites hypnotic depth and pain response, EEG combines with AI in one system, giving clinici real-time control over anesthesia, and hospitals have a smarter, more scalable way to achieve better patient results, both during and after the operation.
Post technical completion BARM 2.0 Clinical tests are planned in the US and the Netherlands to be followed by submissions as quickly as possible to regulatory authorities worldwide.
Cortical Dynamics was invited to present BARM 2.0 on the Australia Regulatory Device Summit 2025, which took place on July 17, July in ICC. In the presence, important stakeholders, including the American FDA, Therapeutic Goods Administration (TGA) and international supervisors from Anvisa (Brazil), HSA (Singapore) and PMDA (Japan). This was a unique opportunity for cortical to come into direct contact with the regulatory community and great global players in medical technology.
Cortical has been selected to show BARM 2.0 at the MedTech on the Hill at Parliament House event in Canberra 27-28 August 22025 organized by Medical Technology Association of Australia (MTAA). In the presence, ministers, members of parliament, senators and industrial leaders will be for an evening network event in Mural Hall, Parliament House. The Showcase brings together a dynamic cross-section of MTAA memberships in therapeutic areas of Australian startups to global medtech leaders who experience hands-on demonstrations through a composite patient journey from prevention to management, and the opportunity to get into direct contact with the people and companies who have innovation in health care.
MTAA is the peak association that represents companies in the medical technology industry. MTAA wants to ensure that the benefits of modern, innovative and reliable medical technology are effectively supplied to offer better health results to the Australian community.
Work continues with the development of Cordyan (TM), the new AI focust predictive app initiative of Cortical Dynamic. The use of an own position of art AI and Deeper Lereldexpertise Cortical Dynamics develops Game -changing medical apps that can be used in collaboration with BARM 2.0 or Standalone and /or are integrated into leading UM health systems and EMR (electronic medical files).
The development of Cordyan (TM) is facilitated by matched subsidies from MTPConnect, the most important medtech government organization of Australia and Arm-Hub, an initiative for the federal government to accelerate AI-related technologies in areas of strategic interest.
Clean Hydrogen Technologies (Cht) (BPH 16.2% Direct interest)
From mid-2024, UCT has developed its engineering and catalyst capacities to a stage where it has been proven consistently in its pilot factory in Nashik, India to produce its 2 products; Turquoise hydrogen and a carbon composite made of majority CNT (carbon nanob.) And CNF (carbon nanophibries), where its core process has no CO2 emissions and the raw material is the hydrocarbons of natural gas. The next phase is the construction of production facilities in the US and India, both are very industrial markets with the demand for Cht’s products.
Since mid-2024, in the first instance, UCT has been designing its production facility for India, which will produce at the end of the phase 1-building, will produce 820 tons of hydrogen and 2,462 tonnes of carbon composite. ATT is planning to sell IT products to the many industrial users in the state of Maharashtra India, the home base of the planned production site, and probably Louisiana, US, identified with different site options.
Before the production needs and cht are completed, the ASME (required for operation in the US) and IS2825 (required for operation in India) has review of the technical designs where this process is almost complete.
CHT is now looking for the financing needed to build its factories in the US and India, where within 3-4 months after minimal financing of US $ 2.5 million will produce income, initially in India and then the US, the primary market.
*To view the full quarterly report, visit:
https://abnnewire.net/lnk/0072553o
About BPH Energy Limited:
BPH Energy Limited (ASX: BPH) is an Australian Securities Exchange -Gain -Gain -Genotated Company that develops biomedical research and technologies within Australian universities and hospital institutions.
The company offers strategies for financing, project management and commercialization at an early stage for direct cooperation, a spin -out company or to secure a license.
BPH offers financing for commercial strategies for proof of concept, research and product development, while the institutional partner offers infrastructure and the nuclear scientific expertise.
BPH currently cooperates with various academic institutions, including the Harry Perkins Institute for Medical Research and Swinburne University of Technology (SUT).
Source:
BPH Energy Limited
#BPH #Energy #Limited #Pep #Update